Three mid-cap stocks—Rumble (RUM), Sellas Life Sciences (SLS) and ADMA Biologics (ADMA)—are drawing investor interest despite limited analyst coverage, with each presenting distinct operational and financial profiles.
Rumble has repositioned itself from a media platform to an AI infrastructure provider, highlighted by a $13.7 billion, six-year GPU services agreement with an unnamed U.S. cloud customer at its Maysville, Georgia facility. The company reports 250 MW of unmonetized grid-connected power capacity, which management estimates could support an annual revenue run rate exceeding $3 billion. In the second quarter, Rumble generated $40.4 million in revenue, up 61% year-over-year, and guided third-quarter revenue to $87–93 million. The stock trades at $9.82, with a market capitalization of $3.74 billion and a year-to-date gain of 53.8%. Analyst coverage remains sparse at one firm, which sets a price target implying 135% upside, valuing the company at roughly 1x enterprise value to revenue—significantly below peers such as CoreWeave and Nebius, which trade at 3.5x forward revenue.
Sellas Life Sciences has surged 683% over the past year and 236% year-to-date, with shares trading at $14.98 near all-time highs. The clinical-stage biotech holds a “Great” financial health rating within its sector, despite coverage from only two analysts. One of those firms projects 126.9% upside from current levels, with a market capitalization of $3.03 billion.
ADMA Biologics, a plasma-derived therapeutics company, has underperformed in 2026, declining 47.8% year-to-date and 44% over the past 12 months. However, the stock has shown signs of stabilization, rising 16.4% over the last three months and 16% in the past month. Trading at $9.59 with a market capitalization of $2.15 billion, ADMA carries a P/E ratio of 13.7x. Five analysts cover the company, with a median target suggesting 78% upside, and the firm holds a “Great” financial health rating.
